Exabis Library
Welcome to the e-CCO Library!
P282: Does colonoscopy alter the post-procedural fecal calprotectin results in Crohn's disease patients with ileocecal resection?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P282: High plasma oncostatin-M predicts non-response to tumour necrosis factor-alpha antagonists in inflammatory bowel disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P282: Influence of phenotype at diagnosis and of other potential prognostic factors on the prognosis of Crohn’s Disease in Chinese population
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P282: Isolated colonic Crohn's disease and extensive ulcerative colitis: is there a reel difference?
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P282: The long-term effect of biologics in newborns
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P283 Patient-reported symptoms over a period of 14 days reliably predict endoscopic and histological disease activity in ulcerative colitis (UC)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P283: Awareness and perceptions of colorectal cancer risk and screening in Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P283: Bowel urgency in patients with moderate to severe ulcerative colitis: prevalence and correlation with clinical outcomes, biomarker levels, and health-related quality of life from U-ACHIEVE, a Phase 2b study of upadacitinib
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P283: Decrease in bowel wall thickness at intestinal ultrasound accurately detects early endoscopic remission and improvement in ulcerative colitis patients on tofacitinib: a longitudinal prospective cohort study.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P283: Development, validation and clinical application of a novel tool to measure disease-related knowledge in patients with inflammatory bowel disease: IBD-KNOW
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P283: Infliximab re-challenge: could it be an option in refractory IBD patients?
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P283: Predicting outcomes in paediatric Crohn’s disease: A systematic review
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P283: Quantum blue® adalimumab: development of the first point of care rapid test for therapeutic drug monitoring of serum adalimumab levels
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P284 Disentangling fibromyalgia from spondyloarthopathy in the patient with inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P284: Assessing Patient Experience in an Inflammatory Bowel Disease service. Can we measure an effect from socioeconomic deprivation – experience from the AWARE-IBD programme?
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P284: Assessment of prothrombotic tendency in IBD pregnant patients and its associated risk factors
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P284: Drug survival and remission rates in ustekinumab treated ulcerative colitis: Results from the Swedish Inflammatory Bowel Disease register (SWIBREG)
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P284: Jejunal Crohn’s disease: characteristics, detection rate, outcome, and need of immunomodulators in a retrospective single-centre study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P284: Prophylactic medication for the prevention of endoscopic recurrence after ileocolonic resection in Crohn’s disease: a prospective study based on clinical risk stratification
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P284: Risk of colorectal neoplasia, colectomy and responsiveness to biologic therapy in patients with inflammatory bowel disease and concomitant primary sclerosing cholangitis: A systematic review
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM